These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34087223)

  • 21. Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway-related proteins.
    Shamaa MM
    FEBS Open Bio; 2021 Mar; 11(3):588-597. PubMed ID: 33289342
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
    Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
    Xue ST; Li K; Gao Y; Zhao LY; Gao Y; Yi H; Jiang JD; Li ZR
    Autophagy; 2020 Oct; 16(10):1823-1837. PubMed ID: 31986961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells.
    Cai H; Yang Y; Peng F; Liu Y; Fu X; Ji B
    Int J Med Sci; 2019; 16(12):1541-1548. PubMed ID: 31839741
    [No Abstract]   [Full Text] [Related]  

  • 25. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells.
    Yao X; Zhao CR; Yin H; Wang K; Gao JJ
    Acta Pharmacol Sin; 2020 Dec; 41(12):1609-1620. PubMed ID: 32300243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted degradation of NDUFS1 by agrimol B promotes mitochondrial ROS accumulation and cytotoxic autophagy arrest in hepatocellular carcinoma.
    Dong L; Luo L; Wang Z; Lian S; Wang M; Wu X; Fan J; Zeng Y; Li S; Lv S; Yang Y; Chen R; Shen E; Yang W; Li C; Wang K
    Free Radic Biol Med; 2024 Aug; 220():111-124. PubMed ID: 38697493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells.
    Ceballos MP; Angel A; Delprato CB; Livore VI; Ferretti AC; Lucci A; Comanzo CG; Alvarez ML; Quiroga AD; Mottino AD; Carrillo MC
    Eur J Pharmacol; 2021 Feb; 892():173736. PubMed ID: 33220273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of SIRT1/AMPK axis is critically involved in gallotannin-induced senescence and impaired autophagy leading to cell death in hepatocellular carcinoma cells.
    Kwon HY; Kim JH; Kim B; Srivastava SK; Kim SH
    Arch Toxicol; 2018 Jan; 92(1):241-257. PubMed ID: 28676953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
    Feng J; Dai W; Mao Y; Wu L; Li J; Chen K; Yu Q; Kong R; Li S; Zhang J; Ji J; Wu J; Mo W; Xu X; Guo C
    J Exp Clin Cancer Res; 2020 Jan; 39(1):24. PubMed ID: 32000827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma.
    Jiang C; Xu R; Li XX; Zhou YF; Xu XY; Yang Y; Wang HY; Zheng XFS
    Mol Cancer Ther; 2018 Dec; 17(12):2610-2621. PubMed ID: 30224431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases.
    Gan G; Shi Z; Shangguan C; Zhang J; Yuan Y; Chen L; Liu W; Li B; Meng S; Xiong W; Mi J
    Theranostics; 2021; 11(12):6006-6018. PubMed ID: 33897895
    [No Abstract]   [Full Text] [Related]  

  • 34. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
    Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
    Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methyl gallate, gallic acid-derived compound, inhibit cell proliferation through increasing ROS production and apoptosis in hepatocellular carcinoma cells.
    Huang CY; Chang YJ; Wei PL; Hung CS; Wang W
    PLoS One; 2021; 16(3):e0248521. PubMed ID: 33725002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
    Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
    Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
    Zhang Z; Yao Z; Wang L; Ding H; Shao J; Chen A; Zhang F; Zheng S
    Autophagy; 2018; 14(12):2083-2103. PubMed ID: 30081711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substituted indole derivatives as UNC-51-like kinase 1 inhibitors: Design, synthesis and anti-hepatocellular carcinoma activity.
    Zhao LY; Li SY; Zhou ZY; Han XY; Li K; Xue ST; Jiang JD
    Biomed Pharmacother; 2024 Sep; 178():117260. PubMed ID: 39116788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.